USA flag logo/image

An Official Website of the United States Government

Electrochemical diagnostics for rapid, multiplexed detection of RA biomarkers

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AR061226
Solicitation Year:
2012
Solicitation Topic Code:
NIAMS
Solicitation Number:
PA09-127
Small Business Information
VIROGENOMICS, INC.
12909 SW 68th Parkway TIGARD, OR -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Electrochemical diagnostics for rapid, multiplexed detection of RA biomarkers
Agency: HHS
Contract: 1R43AR061226-01A1
Award Amount: $281,496.00
 

Abstract:

DESCRIPTION (provided by applicant): Virogenomics is currently developing a portable, electrochemical device for rapid disease diagnosis of multiple indications. The basis of our approach is a patent-pending electrochemical immunoassay performed on patterned electrode arrays, and we take advantage of existing microelectronics technology to create this sensor platform. Importantly, we fabricate our sensors using an attachment method that is broadly reactive, and therefore will allow us to incorporate new ligands onto the device as new biomarker-ligand pairs are discovered. This is accomplished using surfaces that are resistant to non-specific adsorption, enabling the platform to work with complex samples such as serum. The envisioned product will present 6-20+ unique sensors arrayed onto a single support, and will be integrated with fluid handling technologies into a device equipped with hardware and firmware required to do a complete analysis of biomarkers in serum samples and communicate the result. External readers, such as a fluorescent microscope, are not used, enabling a standalone device. The target materials and manufacturing cost for the assay cartridges is 15-50. The target reader instrument cost is 500-1000. The combination of quantitative electrochemical detection with rapid, low-cost diagnosis from multiple biomarkers in a single serum sample will provide a significant improvement to existing technologies. The proposed grant project aims to collaborate closely with the Oregon Health and Science University (OHSU) to establish the feasibility of using the Virogenomics electrochemical assay for use in the multiplexed analysis of 4 serum antibodies linked to Rheumatoid arthritis in a single sample of serum. Using an IRB-approved protocol, we aim to collect serum samples from patients that are positive for RA. We aim to benchmark the performance of our assay against standard ELISA-based methods for the quantitative analysis of serum antibodies. No current array technology has this level of flexibility in design, fabrication and operation for completely electronic (non-optical) diagnostic test. This method is scalable in two dimensions: First, increasing the number of sensor pads in one device will allow for biomarker profiling on a single sample. Second,increasing the number of instrument ports will permit a larger number of human samples to be run at a given time. We aim to open up a new set of tools for use in research and FDA approved diagnostics. PUBLIC HEALTH RELEVANCE: This Phase 1 NIH SBIR project proposes to rapidly assess the feasibility of using an electrochemical diagnostic and instrumentation system for the low-cost, multiplexed detection of serum autoantibodies linked to rheumatoid arthritis. If successful, this technology would betransformative in the clinical diagnosis of rheumatic, musculoskeletal and skin diseases. In addition, this multiplexed test uses a novel attachment chemistry that would be amenable to incorporating new ligands of diagnostic utility as they are discovered.

Principal Investigator:

Jeff King
503-626-8354
jeff.king@virogenomics.com

Business Contact:

Jeffrey King
503-626-8354
jeff.king@virogenomics.com
Small Business Information at Submission:

VIROGENOMICS, INC.
12909 SW 68th Parkway TIGARD, OR -

EIN/Tax ID: 193131912
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No